APPLIED THERAPEUTICS INC. - COMMON STOCK

Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association

21 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia

17 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

01 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference

19 May 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2021 Financial Results

11 May 2021 07:00:02 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

07 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

18 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics to Host Virtual Rare Disease Forum

16 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

23 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Closing of Public Offering

22 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock

11 Feb 2021 18:51:34 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock

10 Feb 2021 16:07:31 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Restart of Pediatric Galactosemia Study

01 Feb 2021 07:00:00 By Nasdaq GlobeNewswire